Our clinically proven and patented ExoSurge® technology uses injected and pulsated gases in tandem with intralesional drug injections to cause the permanent removal of fibrous tissue plaques
associated with a Peyronie's Disease diagnosis.
Our years of research and development devoted to unlocking the epidemiology of Peyronie's plays a key role in our technology's success.
If you are a urologic clinician with potential interest with participating in our upcoming prospective clinical trials, please click here.
If you are a Peyronie’s patient and would like to potentially participate in our upcoming prospective national clinical trials, please click here.
We are science-driven and led by executives and medical advisors. Let us show you our plans to revolutionize the treatment of Peyronie’s disease.
We plan to begin prospective clinical trials in 2025 and will subsequently file for FDA approval for our gas and drug injections in the treatment Peyronie's Disease; our device and drugs combination are not yet available for sale.
Peyronie's Disease: A Growing Challenge
The number of men, from all walks of life, facing consequences from palpable and non-palpable penile fibrosis and Peyronie’s plaques has grown dramatically. However, many have been dealing with the condition for decades, unable to find a successful therapy.
Peyronie's Disease: U.S. Men Under Age 45
Whereas the historical percentage of younger men under the age of 45 years with palpable Peyronie’s fibrosis stayed relatively constant at around 3% for decades, that average has now jumped to 12% – a whopping 300% increase – among US men in that age group. For men under the age of twenty-five, prevalence increased an astounding 900% in the US. The long term trend line among the under-45 crowd is concerning: the incidence rate is increasing 20% every five years.
Peyronie's Disease: US Men Age 45 And Over
The historical percentage of men aged 45 years and over old with a Peyronie’s indication also climbed, from 9% to 13%, a 44% increase.
Our medical research will provide perspective on this phenomenon and how clinicians can better help these patients.
A Global Peyronie’s Challenge
Let’s do the math:
- If the current increase in the number of Peyronie's indications among younger men just maintains its current level continues at its current rate (ignoring the fact it's been increasing at a rate of 20% per year over the last decade)
- And we add the historical nominal average (3%) for new PD diagnosis triggered by accidents and acute penile injury during sex
- The result indicates 20-30% of adult US males could be facing consequences of penile fibrosis and plaques within the next 20 years.
A 2011 population-based study published in Advanced Urology regarding Peyronie’s prevalence by Dibenedetti DB, Nguyen D, Zografos L, et al., indicated about one-third of cases will have a notable impact upon sexual function and a resulting significant impact on relationships, lifestyle, and self-image.
That tally means 9.1% of adult males, or 5.7 million US men will be needing effective treatment in the near future.
Peyronie's Prevalence: We Believe it's much Higher than Estimated
We utilized evidence from the 2016 Perlacky, et al. study of 7,711 American men and the 2011 Di Benedetti, et al. study of 11,420 American respondents. Both were web based which removed the embarrassing element of testimony, both reached very similar conclusions regarding the prevalence of Peyronie's disease, and they both included demographic information that was not found in other studies.
Traditional prevalence estimates for Peyronie's disease have been all over the map, ranging from 0.39% to greater than 20%, with the majority estimating prevalence at approximately 3%.
There was always a "acknowledgement" in these studies that the actual incidence of this disease in the population may be higher due to patients' reluctance to seek treatment and diagnosis for this humiliating condition. The medical community's limited comprehension of PD may also contribute to underdiagnosis.
Because of the "Smith Study" in 1969, which was conducted before the sexual revolution (increased incidence of acute injury) and the advent of new health factors we discovered when unlocking Peyronie's epidemiology, all studies cite a prevalence of up to 20%. B.H. Smith was a US Navy captain working for the Armed Forces Institute of Pathology (AFIP) who had the brilliant notion to examine the prevalence of Peyronie's disease by performing 200 penile cadaver autopsies. He discovered penile fibrosis in nearly 21 percent of the deceased. A future study of European cadavers revealed comparable instances.
We believe that the fact that most urologists diagnose Peyronie's disease through physical examination as opposed to ultrasound imaging is a significant factor in why underreporting has remained so widespread. Inter fibrous plaques have never been effectively treated in urology. Therefore, if a patient reports moderate symptoms, the majority of urologists will ask, "How bothersome is the issue?"
Our investigation into the epidemiology of Peyronie's disease reveals that Peyronie's fibrosis is a progressive condition that never "heals itself." Rather, we encountered instances in which the patient became asymptomatic while the lesions persisted. In the future, when these patients encounter Peyronie's Accelerators, they will experience the symptoms of Peyronie's.
We anticipate that the curative nature of ExoSurge technology and its capacity to treat and heal asymptomatic early-stage cases of penile fibrosis will eventually reveal a prevalence as high as Smith's study (20%), or even higher given the changes in general health and sexual activity since 1969.
Traditional prevalence estimates for Peyronie's disease have been all over the map, ranging from 0.39% to greater than 20%, with the majority estimating prevalence at approximately 3%.
There was always a "acknowledgement" in these studies that the actual incidence of this disease in the population may be higher due to patients' reluctance to seek treatment and diagnosis for this humiliating condition. The medical community's limited comprehension of PD may also contribute to underdiagnosis.
Because of the "Smith Study" in 1969, which was conducted before the sexual revolution (increased incidence of acute injury) and the advent of new health factors we discovered when unlocking Peyronie's epidemiology, all studies cite a prevalence of up to 20%. B.H. Smith was a US Navy captain working for the Armed Forces Institute of Pathology (AFIP) who had the brilliant notion to examine the prevalence of Peyronie's disease by performing 200 penile cadaver autopsies. He discovered penile fibrosis in nearly 21 percent of the deceased. A future study of European cadavers revealed comparable instances.
We believe that the fact that most urologists diagnose Peyronie's disease through physical examination as opposed to ultrasound imaging is a significant factor in why underreporting has remained so widespread. Inter fibrous plaques have never been effectively treated in urology. Therefore, if a patient reports moderate symptoms, the majority of urologists will ask, "How bothersome is the issue?"
Our investigation into the epidemiology of Peyronie's disease reveals that Peyronie's fibrosis is a progressive condition that never "heals itself." Rather, we encountered instances in which the patient became asymptomatic while the lesions persisted. In the future, when these patients encounter Peyronie's Accelerators, they will experience the symptoms of Peyronie's.
We anticipate that the curative nature of ExoSurge technology and its capacity to treat and heal asymptomatic early-stage cases of penile fibrosis will eventually reveal a prevalence as high as Smith's study (20%), or even higher given the changes in general health and sexual activity since 1969.
We expect the permanent removal
of the fibrosis and plaques
associated with a Peyronie's diagnosis
to become a global challenge
for the medical industry in the years ahead.
Over 10 million American men are presently indicated as having Peyronie’s fibrosis and plaques…and cases only get worse with time
Sadly, among the vast majority of patients with a Peyronie’s diagnosis, current methods for treatment are of little or no value. The gold standard of Peyronie’s care remains surgery but is only indicated for select cases and a 2012 10-year retrospective study shows Peyronie’s surgery results in high recurrence rate for erectile dysfunction, Peyronie’s fibrosis and erect curvature.
To date, therapies for treating Peyronie’s disease only vie to treat the various symptoms of the condition: erect curvature, lost length, disfigured shaping, etc. None address the challenge of actually healing the underlying basis for the disease. None are permanent. None effectively treat and heal all cases. Thus, at best, existing treatments offer some patients a temporary reprieve from some of the worst symptoms of Peyronie’s Disease.
ExoSurge® is the world’s first clinically-proven treatment to conservatively and permanently remove plaques and fibrosis associated with a Peyronie’s diagnosis.
For Clinicians
ExoSurge® technology is science-driven, supported by extensive in-clinic use and ongoing clinical research.
We invested over twenty years and $20 million unearthing the etiology and extracellular matrix behind every aspect of Peyronie's Disease manifestation. We understand that your reputation is at stake when you choose to partner with a new technology and that safety and efficacy are paramount to you.
The ExoSurge® Inter-fibrinous Pulsated Gas and Drug Technology (IPG) is the first and only technology of its kind specially engineered to permanently remove the penile fibrosis and Peyronie's plaques that trigger a Peyronie's diagnosis – and it does so safely and without collateral tissue damage. With high patient satisfaction for a conservative procedure, ExoSurge® represents a new way to treat Peyronie's, whether it be from long established penile fibrosis or calcified plaques, active phase penile injury patients, symptoms of early stage Peyronie's such as diffuse penile fibrosis, or preventative care for patients without symptoms but with measurable penile fibrosis that shows up on ultrasound.
Peyronie's Care Reimagined for Clinicians
You'll no longer be treating symptoms, but providing curative outcomes, like:
- Prevention: Testing that identifies susceptible patients in advance of fibrosis and prescribed treatment
- Early Stage Detection and treatment:
- Active Stage Resolution and Repair:
- Established Cases: Both Calcified and Non-calcified cases
- Established Cases: Asymptomatic Case Solution
To learn more about about how we believe ExoSurge® IPG is positioned to revolutionize Peyronie's Disease care, click below.
For Patients
Have you seen the television commercials about "do you have a curve"?
Penile curvature that manifests during an erection is a common sign of Peyronie's. Significant bending occurs in over 60% of Peyronie's case.
However, curvature is just one of the common symptoms. It is not the underlying cause or definition of this disease.
When a disease remains incurable for centuries, its symptoms almost always become society's definition of that disease.
Similarly, the efficacy of the treatments is measured by how well the symptoms are alleviated.
For example, this phenomenon is exemplified by the common cold. Coughing, sneezing, runny nose, sore throat and congestion are the most common symptoms, and people immediately assume we have a cold if we display these symptoms. Nobody inquiries about the type of virus we are fighting, such as rhinovirus, coronavirus, adenovirus, or enterovirus.
Since Peyronie's Disease has remained similarly incurable, it has likewise become only known for its symptoms, even among many physicians, with erect curvature being the most notable definition. Thus, every approved treatment and medication for Peyronies is evaluated solely based on its efficacy in reducing erect curvature.
This is what makes ExoSurge® completely different from anything ever used to treat Peyronie’s.
ExoSurge® technology treats, heals and cures the underlying disease of Peyronie’s, not just its symptoms.
ExoSurge® is the world's first clinically-proven treatment to conservatively and permanently remove plaques and fibrosis associated with a Peyronie's diagnosis.
Our Technology
The ExoSurge® Inter-fibrinous Pulsated Gaseous Technology (IPG) uses a sequenced three-step gas and drug process within every 20-minute treatment, which results in measurable permanent reduction or softening of penile fibrosis during each visit. Our new pulsated gas and drug treatment technology has resulted in 15 patent filed or granted applications from our team of medical professionals and engineers.
Our Inter-fibrinous Pulsated Gas Technology (IPG) delivers a treatment that is well tolerated, generates no heat or collateral tissue damage, requires no patient downtime or anesthesia, and works without regard to patient skin color.
IPG technology is a novel and distinctive method of drug administration. It has been clinically proven to transform long-known generic intralesional Peyronie's medications into "super drugs" that produce curative results in which Peyronie's fibrosis is broken up and dissolved into the body, just as is expected to occur when the body initiates a fibrotic response in response to injury.
Dive deeper into the technology and our plans for the future from the link below.
What do ExoSurge® patients say about our Peyronie's technology?
The following are verified patient reviews. Our clinic has supporting documentation. Edits have occasionally been made to correct grammatical or spelling errors.
Stay Up To Date
If you are a Peyronie's patient who has interest in participating in one of our upcoming clinical trials around the United States, please click here
If you are a urologic clinician who has a potential interest with being involved in our upcoming prospective clinical trials, please click here
If you would like to stay abreast of our progress during clinical trials and in the future, please click here:
Sign up to follow our story and to watch us grow!